Stocktoria
Nuvalent, Inc. NUVL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-29
Nuvalent, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $307.0M | $217.8M | $113.2M | $63.7M | $35.6M |
| Operating income | -$414.3M | -$280.4M | -$149.5M | -$86.1M | -$45.8M |
| Income tax | $585,000 | $764,000 | $0 | $0 | — |
| Net income | -$425.4M | -$260.8M | -$126.2M | -$81.9M | -$46.3M |
| EPS (diluted) | $-5.85 | $-3.93 | $-2.17 | $-1.65 | $-2.13 |
| Operating cash flow | -$275.2M | -$185.1M | -$99.7M | -$65.0M | -$40.0M |
| Cash & equivalents | $261.7M | $145.7M | $335.4M | $241.8M | $68.5M |
| Total assets | $1.4B | $1.1B | $732.4M | $482.5M | $293.8M |
| Total liabilities | $164.4M | $72.0M | $31.8M | $19.5M | $8.8M |
| Shareholders' equity | $1.2B | $1.1B | $700.6M | $463.0M | $285.0M |
Source: SEC EDGAR filings · CIK 0001861560 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.